Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

32 results about "Orodispersible film" patented technology

A personalised orodispersible film can be printed on-site by the pharmacist in order to respond to the needs of the individual patient (Alomari et al., 2014, Lind et al., 2016). For instance, the required therapeutic dose can be adjusted on-site in particular benefitting paediatric patients.

Desloratadine oral dispersible film

The invention relates to a desloratadine oral dispersible film which comprises desloratadine, biologically-acceptable water-soluble polymers, plasticizers, purified water and the like, can be dispersed or dissolved quickly in the oral cavity, and is used for treating allergic rhinitis, allergic rhinitis and asthma syndrome, allergic nasal conjunctivitis, allergic dermatitis, allergic asthma and the like. The desloratadine oral dispersible film is free of irritation, convenient to take and carry, fast in effect, good in taste and particularly suitable for being used by the olds and children.
Owner:BEIJING RUNDEKANG MEDICAL TECH CO LTD

Oxiracetam oral dispersion membrane preparation and preparation method thereof

The invention relates to an oxiracetam oral dispersion membrane preparation and a preparation method thereof. The oxiracetam oral dispersion membrane preparation is prepared from a composite membrane forming material, a plasticizing agent, a filling agent and the like. The oxiracetam oral dispersion membrane preparation has the advantages that the preparation can be dissolved by less saliva in an oral cavity, and can be taken without using water, so that the taking is convenient; the easiness in vomiting is avoided after sticking onto a tongue, and the Oxiracetam oral preparation is suitable for patients with difficulty in swallowing; by utilizing mucosae to absorb, the first pass elimination effect is avoided, the bioavailability is improved, the medicine dosage is reduced, and the side effect is decreased. The preparation method has the advantages that the preparation technology is simple, and the preparation method is suitable for industrialized production.
Owner:CHONGQING RUNZE PHARM CO LTD

Orodispersible films having quick dissolution times for therapeutic and food use

The present invention concerns an orodispersible self-supporting film free from hydrocolloids comprising:a) a film-forming substance consisting of a maltodextrin in an amount comprised between 40 and 80% by weight;b) one or more plasticizer in a total amount comprised between 15 and 55% by weight;e) a surfactant System in an amount comprised between 0.5 and 6% by weight;d) an active ingredient for food or therapeutic use in an amount between 0.05 and 30% by weight,said orodispersible self-supporting film free from hydrocolloids further containing a homopolymer or a copolymer of vinyl acetate in a quantity comprised between 1 and 20% by weight where the percentages are calculated on the total weight of said film.
Owner:PHARMAFILM

Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population

The present invention relates to an oral applicable therapeutic dosage form, in particular an orodispersible film comprising Enalapril or pharmaceutically acceptable salts thereof for use in the treatment of hypertension in a pediatric population. The pediatric population is defined from 1 to 18 years of age. The present invention also provides a method of manufacturing of such a dosage form.
Owner:PHARMATHEN

Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population

The present invention relates to an oral applicable therapeutic dosage form, in particular an orodispersible film comprising Enalapril or pharmaceutically acceptable salts thereof for use in the treatment of hypertension in a pediatric population. The pediatric population is defined from 1 to 18 years of age. The present invention also provides a method of manufacturing of such a dosage form.
Owner:PHARMATHEN

Oral dispersible film composition

Pharmaceutical and nutraceutical composition in the form of oral dispersible films (ODFs) using twin-screw hot melt extrusion was described. In the present disclosure, there is provided an oral dispersible film composition comprising: (a) maltodextrin; and (b) hydroxypropyl cellulose, wherein the weight ratio of maltodextrin to hydroxypropyl cellulose is in the range of 1:1-3:1. The prepared films of pharmaceutical and nutraceutical composition are uniform in film thickness, have excellent physical attributes and can be directly packed after cutting.
Owner:JUBELN LIFESCI PVT LTD

Tadalafil oral dispersible film and preparing method thereof

The present disclosure relates to compositions for preparing an oral dispersible film comprising tadalafil or its pharmaceutically acceptable salt thereof, surfactant, plasticizer and sweetening agent; an oral dispersible film; and methods of preparing thereof. The oral dispersible film of the present disclosure can improve dissolution rate of the tadalafil without complicated processes and has superior stability compared to previous Cialis because generation of related compounds are inhibited regardless of existence of a packaging. Additionally, superior film properties comprising prevention of film breakage, securement of flexibility and prevention of oil leakage from film formulation can be maintained when comprising specific content of a polyethylene glycol 400 as the plasticizers.
Owner:SEOUL PHARMA

Oral dissolving film preparation containing bulleyaconitine A and preparation technology of oral dissolving film preparation

The invention belongs to the field of medicinal preparations, and discloses an oral dissolving film preparation containing bulleyaconitine A and a preparation technology of the oral dissolving film preparation. The dissolving film contains bulleyaconitine A, polyacrylic resin II, a film forming substrate, a sweetening agent, a saliva irritant and essence. With the dissolving film, the tingling sensation and bitter taste of bulleyaconitine A can be well masked, and the preparation method is simple and feasible.
Owner:YUNNAN INST OF MATERIA MEDICA

Method for preparing levorotatory oxiracetam oral dispersible film preparation

InactiveCN106821957ASolve the prone to softnessSolve the problem of poor film formationOrganic active ingredientsNervous disorderMedicinePlasticizer
The invention discloses a method for preparing a levorotatory oxiracetam oral dispersible film preparation. The levorotatory oxiracetam oral dispersible film preparation is made by using a film forming material, a plasticizer, a filling agent, a saliva irritant, correctant and levorotatory oxiracetam as raw materials and through coating, drying and stripping by using a film coating and drying machine for a medicinal film. According to the method, the levorotatory oxiracetam oral dispersible film preparation is prepared by using a film coating machine for the medicinal film; the thickness, the coating speed and the drying temperature of the oral dispersible film preparation are strictly controlled; thus, the process is stabilized; the quality of a product is guaranteed; aspects of the brittlement, the disintegration time limit, the dissolution time and the like of the levorotatory oxiracetam oral dispersible film are enabled to be more beneficial to clinical application.
Owner:CHONGQING RUNZE PHARM CO LTD

L-oxiracetam oral dispersible membrane and preparation method thereof

The invention relates to an L-oxiracetam oral dispersible membrane and a preparation method thereof. The L-oxiracetam oral dispersible membrane is prepared by adopting materials, such as a composite membrane-forming material, a plasticizer and a filler. After being stuck to the tongue, the L-oxiracetam oral dispersible membrane cannot be easily spit out, and therefore is suitable for old people with dysphagia. Moreover, because the L-oxiracetam oral dispersible membrane can be absorbed through the mucous membrane, the first pass elimination effect is prevented, the bioavailability is increased, the dosage of medication is reduced, and thereby the side effect of the medicine is reduced. The preparation process of the invention is simple, and therefore is suitable for industrialized production.
Owner:CHONGQING RUNZE PHARM CO LTD

Dextromethorphan hydrobromide oral dispersible film agent and preparation method thereof

The invention provides a dextromethorphan hydrobromide oral dispersible film agent. The film agent comprises dextromethorphan hydrobromide, polacrilin or polacrilin potassium with grain diameter of 50-150mu m, a film forming agent, a plasticizer, a disintegrating agent, a wetting agent and water, wherein dextromethorphan hydrobromide and polacrilin or polacrilin potassium form a dextromethorphan hydrobromide compound, and the weight ratio of dextromethorphan hydrobromide to polacrilin or polacrilin potassium is 1:1-1:2, and preferably 1:1.3-1:1.5; the film forming agent comprises hydroxypropyl methylcellulose E3 and hydroxypropyl methylcellulose E50. The invention also provides a preparation method of the dextromethorphan hydrobromide oral dispersible film agent. The dextromethorphan hydrobromide oral dispersible film agent can well solve the problem of poor taste of dextromethorphan hydrobromide, is particularly suitable for children and old patients, and can remarkably improve the compliance of patients. An oral film tablet is nicer by an optimal preparation method.
Owner:山西皇城相府药业股份有限公司

Levo oxiracetam oral cavity dispersing film preparation, and preparation method thereof

The invention discloses a levo oxiracetam oral cavity dispersing film preparation. The levo oxiracetam oral cavity dispersing film preparation comprises 1 to 15 parts of levo oxiracetam, 85 to 95 parts of a film forming material, 5 to 10 parts of a plasticizer, and 2 to 5 parts of a saliva irritant. According to the preparation method, the above raw materials are subjected to full grinding and uniform mixing, and are delivered into a hot-melt lamination machine for extrusion so as to obtain a finished product. The appearance of the obtained levo oxiracetam oral cavity dispersing film preparation is complete, color is uniform, thickness is uniform, physical and chemical properties are stable, in oral cavity, the levo oxiracetam oral cavity dispersing film preparation can be dissolved with a small amount of saliva, taking of the levo oxiracetam oral cavity dispersing film preparation with water is not necessary, the levo oxiracetam oral cavity dispersing film preparation is convenient to eat, and the preparation method is simple, and is suitable for industrialized production.
Owner:CHONGQING RUNZE PHARM CO LTD

Loratadine oral dispersible film agent and preparation method thereof

The invention relates to an loratadine oral dispersible film agent. The loratadine oral dispersible film agent is prepared from the following raw and auxiliary materials in percentage by mass of 25-40% of loratadine, 0.3-1% of polysorbate 80, 1-10% of plasticizer, 0.001-0.02% of glyceride fatty acid, 2-5% of povidone K30, 22-35% of hypromellose-E5, 10-25% of hydroxypropyl cellulose-SL, 1-8% of maltose, 0.5-5% of saccharin sodium, and 1-6% of opacifier; and the particle size X90 of loratadine is less than or equal to 10 mu m. The preparation process disclosed by the invention is simple and controllable, and is suitable for industrial mass production; the prepared oral dispersible film agent has significantly improved tensile strength, disintegration speed, taste and stability, has the advantages of high drug loading capacity, small volume, convenience in carrying, dosage control and administration, and rapid disintegration in the oral cavity without drinking water, realizes rapid release of active ingredients of the drug, has good taste and is easy to accept, and compliance and the safety of children medication are improved.
Owner:JIANMIN PHARMA GRP CO LTD

High bioavailability oromucosal pharmaceutical preparations based on cyclodextrin and sucralose

The invention relates to a new composite based on hydroxypropyl-beta-cyclodextrin, sucralose, a pharmaceutically active ingredient (API) complexed in said hydroxypropyl-beta-cyclodextrin, and optionally an aqueous vehicle. The composite is obtainable by a complexation process of the API in hydroxypropyl-beta-cyclodextrin, carried out in the presence of sucralose. The composite ensures a surprisingly high API bioavailability through buccal route of absorption, due to a high absorption rate through the oral membrane. The composite is therefore suitable for the preparation of oromucosal pharmaceutical compositions, e.g. buccal or sublingual tablets, orodispersible film, etc., having high bioavailability.
Owner:ALTERGON

Orodispersible film

The present invention relates to orodispersible films comprising a plant extract and to film forming suspensions comprising a plant extract. Further, the present invention relates to processes for preparing the orodispersible films and the film forming suspensions.
Owner:HEXAL AG

Method for preparing oxiracetam oral dispersible film preparation

The invention discloses a method for preparing an oxiracetam oral dispersible film preparation. The method comprises the following steps of sufficiently grinding and uniformly mixing 1 to 15 parts of oxiracetam, 80 to 95 parts of film forming material, 5 to 10 parts of plasticizer, 2 to 5 parts of saliva irritant and 1 to 3 parts of sweetener, sending a mixture to a hot melting zone through a feeding zone of a hot-melt film laminator, hot melting the mixture at 70 to 95 DEG C, continuously outputting the molten mixture through a proportioning zone, pouring the molten mixture into a mold, and cooling the mixture to form the film preparation. According to the method, the film forming material of specific type and use level is selected to be combined with the plasticizer; thus, technical problems that the film preparation is easy to break, is poor in strength and toughness, is slow to disintegrate, is longer in dissolution time and is not beneficial to the absorption of a medicine, and the like, are solved; the made oxiracetam oral dispersible film preparation is enabled to be good in demolding performance; a medicinal film is flexible, is uneasy to break, and is short in the dissolution time.
Owner:CHONGQING RUNZE PHARM CO LTD

Tadalafil orodispersible film and preparation method thereof

The present disclosure relates to a composition for preparing an orodispersible film, which comprises tadalafil or a pharmaceutically acceptable salt thereof, a surfactant, a plasticizer and a sweetener; an orodispersible film; and a preparation method thereof . The orodispersible film of the present disclosure can improve the dissolution rate of tadalafil without a complicated process, and it has excellent stability compared with the previous Cialis because the generation of related compounds is suppressed regardless of the presence or absence of packaging. In addition, when polyethylene glycol 400 is included in a specific content as a plasticizer, excellent film properties can be maintained, including preventing film breakage, securing flexibility, and preventing oil leakage of film formulations.
Owner:SEOUL PHARMA

Structured orodispersible films

Disclosed is a method for producing a porous orodispersible film, having the following steps: i) forming a suspension of a pharmaceutically acceptable solvent, a pharmaceutically acceptable matrix material, and a pharmaceutically acceptable binder, said solvent being selected such that the pharmaceutically acceptable matrix material substantially does not dissolve in it, whereas the pharmaceutically acceptable binder is dissolved in the solvent, ii) casting the suspension onto a neutral support, thereby forming a wet film, and iii) drying the wet film and obtaining a dry film. The films produced in this manner have a closed surface on the lower face whereas the upper face is porous, thereby allowing the application of a pharmaceutically active ingredient in the form of a suspension or a solution for example. This allows the active ingredient quantity to be adjusted individually to the particular application and produces a film base material which is suitable for the application of different active ingredients.
Owner:LTS LOHMANN THERAPIE-SYST AG

Orodispersible films having quick dissolution times for therapeutic and food use

The present invention concerns an orodispersible self-supporting film free from hydrocolloids comprising: a) a film-forming substance consisting of a maltodextrin in an amount comprised between 40 and 80% by weight; b) a plasticizer in an amount comprised between 15 and 55% by weight; e) a surfactant System in an amount comprised between 0.5 and 6% by weight; d) an active ingredient for food or therapeutic use in an amount between 0.05 and 30% by weight, characterised in that it contains a homopolymer or a copolymer of vinyl acetate in a quantity comprised between 2 and 10% by weight where the percentages are calculated on the total weight of said film
Owner:PHARMAFILM

Warfarin sodium oral cavity dispersion film agent and preparation method thereof

The invention discloses a warfarin sodium oral cavity dispersion film agent easy for dose deviding, and a preparation method thereof, which belong to the technical field of medicines. The designed warfarin sodium oral cavity dispersion film agent is prepared from warfarin sodium, a film-forming material and a plasticizer. According to the preparation method provided by the invention, the film agent is prepared through a flow casting method, is smooth and clean in surface, and can be quickly dissolved to release medicine when encountering water, so that the warfarin sodium is favorably orally absorbed. In order to achieve the aim of easiness in dose deviding, scale identification is carried out on a warfarin sodium oral cavity dispersion film, and the dosage can be flexibly adjusted according to the length of the film, so that the use is convenient. Through preparing the warfarin sodium oral cavity dispersion film agent, the defects that dose deviding on a traditional warfarin sodium tablet is not easy and is inaccurate in clinic treatment are overcome, and the warfarin sodium oral cavity dispersion film agent is an oral anticoagulant more suitable for clinic personalized medication.
Owner:CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products